Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Araceli, Mezcua"'
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
Autor:
Borja Hernández-Breijo, Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Ioannis Parodis, Johanna E. Gehin, Ana Martínez-Feito, Marta Novella-Navarro, Araceli Mezcua, David J. Warren, Pilar Nozal, Dora Pascual-Salcedo, Alejandro Balsa
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in th
Externí odkaz:
https://doaj.org/article/23161f74c66b452fadeaadcaeff92d76
BAFF Predicts Immunogenicity in Older Patients With Rheumatoid Arthritis Treated With TNF Inhibitors
Autor:
Borja Hernández-Breijo, Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Ioannis Parodis, Johanna E. Gehin, Ana Martínez-Feito, Marta Novella-Navarro, Araceli Mezcua, David J. Warren, Pilar Nozal, Dora Pascual-Salcedo, Alejandro Balsa
Background: Immunogenicity related to treatment with TNF inhibitors (TNFi) is one of the causes for the decreased attainment of clinical response in patients with rheumatoid arthritis (RA). The B-cell activating factor (BAFF) may be playing a role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17c6f0ede83a9fee929450a93740ccba
https://doi.org/10.21203/rs.3.rs-74233/v1
https://doi.org/10.21203/rs.3.rs-74233/v1
Autor:
Ana, Martínez-Feito, Chamaida, Plasencia-Rodriguez, Victoria, Navarro-Compán, Teresa, Jurado, Eva Linda, Kneepkens, Gertjan J, Wolbink, Sergio, Martín, Ainhoa, Ruiz Del Agua, Rosaura, Navarro, Araceli, Mezcua, Andrea, Jochems, Diana, Peiteado, Maria Gema, Bonilla, Alejandro, Balsa, Dora, Pascual-Salcedo
Publikováno v:
Clinical and experimental rheumatology. 36(1)
Objective To investigate the association between serum golimumab (GLM) trough levels, clinical disease activity and treatment response during the first year of therapy in patients with axial spondyloarthritis (axSpA), as well as determining an optima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::54dd1b20f123539cb56a375edc228113
https://pubmed.ncbi.nlm.nih.gov/28980904
https://pubmed.ncbi.nlm.nih.gov/28980904